Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
GlaxoSmithKline |
---|---|
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00554255 |
To investigate the safety and tolerability, PK and PD of SB751689 following single and 5-day multiple oral doses of 100, 200, and 400 mg in Japanese postmenopausal subjects.
Condition | Intervention | Phase |
---|---|---|
Postmenopausal Women |
Drug: SB751689 |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Single Blind (Subject), Crossover Assignment, Safety Study |
Official Title: | Phase I Study of SB751689 - Single and Multiple Oral Dose Study in Japanese Postmenopausal Women - |
Estimated Enrollment: | 18 |
Study Start Date: | October 2006 |
Ages Eligible for Study: | 50 Years to 70 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | GSK ( Study Director ) |
Study ID Numbers: | 108543 |
Study First Received: | November 2, 2007 |
Last Updated: | October 13, 2008 |
ClinicalTrials.gov Identifier: | NCT00554255 |
Health Authority: | Japan: Ministry of Health, Labor and Welfare |
safety Pharmacokinetics Pharmacodynamics Japanese |